Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 4, 2025

Hu CD45 BUV395 HI30 100Tst

RRID:AB_2869519 Type: Antibody

Proper Citation

(BD Biosciences Cat# 563792, RRID:AB_2869519)

Antibody Information

URL: http://antibodyregistry.org/AB_2869519

Proper Citation: (BD Biosciences Cat# 563792, RRID:AB_2869519)

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Hu CD45 BUV395 HI30 100Tst

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: HI30

Antibody ID: AB_2869519

Vendor: BD Biosciences

Catalog Number: 563792

Record Creation Time: 20241016T223651+0000

Record Last Update: 20241016T231249+0000

Ratings and Alerts

No rating or validation information has been found for Hu CD45 BUV395 HI30 100Tst.

No alerts have been found for Hu CD45 BUV395 HI30 100Tst.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Li Z, et al. (2024) Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell, 187(3), 624.

Hammer Q, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell stem cell, 31(9), 1376.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. Cell reports, 43(2), 113712.

Huang YH, et al. (2024) Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. Cell reports. Medicine, 5(2), 101416.

Li Z, et al. (2024) Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors. STAR protocols, 5(3), 103096.

Fiore G, et al. (2024) Human CD34+-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy. Frontiers in immunology, 15, 1433119.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. Cell reports, 44(1), 115102.

Lu L, et al. (2023) STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells. Cell reports, 42(9), 113108.

Ming Z, et al. (2023) IFN-? Signaling Sensitizes Melanoma Cells to BH3 Mimetics. The Journal of investigative dermatology, 143(7), 1246.

Goulding J, et al. (2023) A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors. Med (New York, N.Y.), 4(7), 457.

Nuñez NG, et al. (2023) Immune signatures predict development of autoimmune toxicity in

patients with cancer treated with immune checkpoint inhibitors. Med (New York, N.Y.), 4(2), 113.

Ryan FJ, et al. (2023) A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. Cell reports. Medicine, 4(3), 100971.

Otte F, et al. (2023) Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods. Cell reports methods, 3(6), 100485.

Grünhagel B, et al. (2023) Reduction of IFN-I responses by plasmacytoid dendritic cells in a longitudinal trans men cohort. iScience, 26(11), 108209.

Philpott JD, et al. (2023) Antigen-specific T cell responses in SARS-CoV-2 mRNA-vaccinated children. Cell reports. Medicine, 4(12), 101298.

Krämer B, et al. (2023) Single-cell RNA sequencing identifies a population of human liver-type ILC1s. Cell reports, 42(1), 111937.

Wang Y, et al. (2023) Intratumoral erythroblastic islands restrain anti-tumor immunity in hepatoblastoma. Cell reports. Medicine, 4(5), 101044.

Lakerveld AJ, et al. (2023) Binding of respiratory syncytial virus particles to platelets does not result in their degranulation in vitro. Access microbiology, 5(7).

Moquin-Beaudry G, et al. (2022) Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions. Cell reports methods, 2(1), 100153.

Yang C, et al. (2022) Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity. Immunity, 55(7), 1268.